Navigation Links
Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
Date:9/19/2013

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, quizartinib, at 8:30 a.m. EDT.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.Ambit Contacts:Marcy Graham

Ian Stone/
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
2. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
3. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
4. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. Natural Skin Care Solution, Probiotic Action Announces the Use of Their Probiotic Cleanser As a Anti-Acne Body Wash
9. Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
10. Neogen announces 1st quarter results conference call
11. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... “This kit has an improved extraction efficiency ... to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager ... plant owners and USDA-GIPSA inspection agencies that have a need ... take place in a matter of minutes with nothing but ... the feed and grain before accepting it, but they no ...
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... 2014  Armetheon, Inc. ( www.armetheon.com ), a ... late-stage cardiovascular drug candidates, today announced that it ... of financing. The Series A round was co-led ... participation from investors that included Atheneos Capital and ... Larry Hsu , the founder of Impax Laboratories. ...
(Date:8/28/2014)... Earlier this month, a report was ... the U.S. Air Force on the performance of vehicles ... this type of fuel made from mustard seeds, offered ... to America’s Eco friendly future. In fact, every branch ... become independent of foreign oil over the next few ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... New President/CEO and Executive Chairman Set Sights on ... Cell Biology, BOSTON, SAN DIEGO, SAN FRANCISCO ... John Mendlein have joined Fate Therapeutics as,president and ... a team of internationally recognized stem cell scientists,clinicians ...
... Sagent Pharmaceuticals, Inc.,a privately-held specialty pharmaceutical company, ... American Red Cross to assist the victims,of Monday,s ... of the global community, we were saddened by ... province," said Jeffrey M. Yordon,chief executive officer, founder, ...
... May 14 Simcere Pharmaceutical,Group (NYSE: SCR ), a ... the patented anti-cancer biotech,product Endu in China, today announced that ... * Brean Murray Carret & Co. All ... in New York on Monday, May 19, 2008 at 2:00 ...
Cached Biology Technology:Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York 2
(Date:8/28/2014)... Clinic researcher and his collaborators have developed an online ... process of re-engineering cells for biomedical investigation. CellNet is ... to aid stem cell engineering. Details of CellNet and ... two back-to-back papers in the journal Cell . ... uses for all types of cell-based investigations and can ...
(Date:8/28/2014)... Athens, Ga. The support of peer groups ... effective breastfeeding programs, according to recent University of ... mothers in the Athens-Clarke County area determined that ... the outcomes of mothers of infants. , "Mothers ... be successful at breastfeeding," said study co-author Alex ...
(Date:8/28/2014)... A unique method for delivering compounds that ... HIV and AIDS may be possible, thanks ... Agricultural Sciences., A semi-soft vaginal suppository made ... loaded with the antiviral drug Tenofovir provides ... against the spread of sexually transmitted infections ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Breastfeeding study shows need for effective peer counseling programs 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3
... examination of the first direct and detailed climate record ... last remnant of Antarctic vegetation existed in a tundra ... years ago. The research, which was led by researchers ... this week and will be featured on the cover ...
... some very interesting passengers on the final mission of ... 8, 2011: thousands of bacteria. Cynthia Collins, ... is leading a series of experiments called Micro-2A that ... mission. The research seeks to understand how microgravity changes ...
... tools and techniques for achieving targeted gene delivery and ... the successful application of gene therapy to treat a ... are presented in a series of five provocative articles ... , a peer-reviewed journal published by Mary Ann Liebert, ...
Cached Biology News:Fossilized pollen reveals climate history of northern Antarctica 2Fossilized pollen reveals climate history of northern Antarctica 3Engineer to launch bacteria into space aboard the final mission of Space Shuttle Atlantis 2Engineer to launch bacteria into space aboard the final mission of Space Shuttle Atlantis 3The promise of stem cell-based gene therapy 2
... VIP (6-28) (human, bovine, ... Intestinal Peptide (VIP) receptor antagonist. ... found to be twofold more ... VIP receptor antagonists. ...
Request Info...
... mini Tray (3 per pack), 1. ... and blot processing.Automated staining of Coomassie ... and nucleic acid analysis.Prepares blots for ... detection.Programmable control of protocol, solution, volume, ...
... High quality kits and reagents ... give consistent and reliable 2-D ... up samples from contaminants.Efficiently dialyze ... protein for first-dimension isoelectric focusing.Reagents ...
Biology Products: